{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T18:28:46Z","timestamp":1789496926608,"version":"build-2803163510"},"reference-count":238,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.bioorg.2026.109706","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T17:06:14Z","timestamp":1772125574000},"page":"109706","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Rational design of dual ALK inhibitors: scaffolds and strategies to circumvent drug resistance"],"prefix":"10.1016","volume":"174","author":[{"given":"Tawfeek A.A.","family":"Yahya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa A.","family":"Al-Qadhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.bioorg.2026.109706_bb0005","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.cell.2010.06.011","article-title":"Cell signaling by receptor tyrosine kinases","volume":"141","author":"Lemmon","year":"2010","journal-title":"Cell"},{"issue":"5151","key":"10.1016\/j.bioorg.2026.109706_bb0010","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1126\/science.8122112","article-title":"Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin\u2019s lymphoma","volume":"263","author":"Morris","year":"1994","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.bioorg.2026.109706_bb0015","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1016\/j.bmcl.2016.03.017","article-title":"Design and synthesis of novel 3-Sulfonylpyrazol-4-amino pyrimidines as potent anaplastic lymphoma kinase (ALK) inhibitors","volume":"26","author":"Zhang","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2026.109706_bb0020","article-title":"ALK fusions in the pan-cancer setting: another tumor-agnostic target?","volume":"7","author":"Shreenivas","year":"2023","journal-title":"Npj precis. Oncol."},{"issue":"Suppl. 3","key":"10.1016\/j.bioorg.2026.109706_bb0025","article-title":"The role of the ALK receptor in Cancer biology","volume":"27","author":"Hallberg","year":"2016","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.bioorg.2026.109706_bb0030","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1042\/BJ20100609","article-title":"Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain","volume":"430","author":"Lee","year":"2010","journal-title":"Biochem. J."},{"issue":"12","key":"10.1016\/j.bioorg.2026.109706_bb0035","doi-asserted-by":"crossref","first-page":"164","DOI":"10.3390\/cancers9120164","article-title":"Non-canonical thinking for targeting ALK-fusion Oncoproteins in lung Cancer","volume":"9","author":"Wu","year":"2017","journal-title":"Cancers"},{"key":"10.1016\/j.bioorg.2026.109706_bb0040","doi-asserted-by":"crossref","first-page":"R11","DOI":"10.1530\/JME-11-0004","article-title":"European T-cell lymphoma study group. Anaplastic lymphoma kinase in human Cancer","volume":"47","author":"Barreca","year":"2011","journal-title":"J. Mol. Endocrinol."},{"key":"10.1016\/j.bioorg.2026.109706_bb0045","doi-asserted-by":"crossref","DOI":"10.1101\/mcs.a001115","article-title":"ALK: a tyrosine kinase target for Cancer therapy","volume":"3","author":"Holla","year":"2017","journal-title":"Cold Spring Harb. Mol. Case Stud."},{"key":"10.1016\/j.bioorg.2026.109706_bb0050","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nature05945","article-title":"Identification of the transforming EML4\u2013ALK fusion gene in non\u2013Small-cell lung Cancer","volume":"448","author":"Soda","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2026.109706_bb0055","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/nrc3580","article-title":"Mechanistic insight into ALK receptor tyrosine kinase in human Cancer biology","volume":"13","author":"Hallberg","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bioorg.2026.109706_bb0060","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1182\/blood-2007-04-060715","article-title":"Pathobiology of ALK-positive anaplastic large-cell lymphoma","volume":"110","author":"Amin","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bioorg.2026.109706_bb0065","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1158\/2159-8290.CD-14-0377","article-title":"Inflammatory Myofibroblastic Tumors Harbor multiple potentially actionable kinase fusions","volume":"4","author":"Lovly","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bioorg.2026.109706_bb0070","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1200\/JCO.2009.22.6993","article-title":"Clinical features and outcome of patients with non\u2013Small-cell lung Cancer who harbor EML4\u2013ALK","volume":"27","author":"Shaw","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2026.109706_bb0075","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.phrs.2012.11.007","article-title":"Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition","volume":"68","author":"Roskoski","year":"2013","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bioorg.2026.109706_bb0080","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1517\/17460441.2013.813015","article-title":"The preclinical profile of crizotinib for the treatment of non\u2013small cell lung cancer and other neoplastic disorders","volume":"8","author":"Roskoski","year":"2013","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.bioorg.2026.109706_bb0085","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1056\/NEJMoa1006448","article-title":"Anaplastic lymphoma kinase inhibition in non\u2013Small-cell lung Cancer","volume":"363","author":"Kwak","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bioorg.2026.109706_bb0090","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1056\/NEJMoa1810171","article-title":"Brigatinib versus crizotinib in ALK-positive non\u2013Small-cell lung cancer","volume":"379","author":"Camidge","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bioorg.2026.109706_bb0095","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1200\/JCO.2015.63.9443","article-title":"Alectinib in crizotinib-refractory ALK-rearranged non\u2013Small-cell lung cancer: a phase II global study","volume":"34","author":"Ou","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2026.109706_bb0100","first-page":"210","article-title":"Lorlatinib in non\u2013Small-cell lung cancer with ALK or ROS1 rearrangement: results of the global phase 2 study","volume":"21","author":"Shaw","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bioorg.2026.109706_bb0105","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","article-title":"First-line Lorlatinib or Crizotinib in advanced ALK-positive lung Cancer","volume":"383","author":"Shaw","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bioorg.2026.109706_bb0110","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1158\/2159-8290.CD-18-0484","article-title":"Repotrectinib (TPX-0005) is a next-generation ROS1\/TRK\/ALK inhibitor that potently inhibits solvent-front mutations","volume":"8","author":"Drilon","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bioorg.2026.109706_bb0115","article-title":"Anaplastic lymphoma kinase (ALK) inhibitors in the treatment of ALK-driven lung cancers","volume":"146","author":"Roskoski","year":"2019","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bioorg.2026.109706_bb0120","first-page":"330","article-title":"ALK-positive lung Cancer: a moving target","volume":"4","author":"Schneider","year":"2023","journal-title":"Nat. Can."},{"key":"10.1016\/j.bioorg.2026.109706_bb0125","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMoa1508887","article-title":"Resensitization to Crizotinib by the Lorlatinib-resistant ALK mutation L1198F","volume":"374","author":"Shaw","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bioorg.2026.109706_bb0130","first-page":"20","article-title":"ALK inhibitors in Cancer: mechanisms of resistance and therapeutic management strategies","volume":"7","author":"Poei","year":"2024","journal-title":"Cancer Drug Resist."},{"key":"10.1016\/j.bioorg.2026.109706_bb0135","doi-asserted-by":"crossref","first-page":"10927","DOI":"10.1021\/acs.jmedchem.9b00446","article-title":"Drug discovery targeting anaplastic lymphoma kinase (ALK)","volume":"62","author":"Kong","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109706_bb0140","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1285374","article-title":"Anaplastic lymphoma kinase inhibitors\u2014a review of anticancer properties, clinical efficacy, and resistance mechanisms","volume":"14","author":"Kie\u0142bowski","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bioorg.2026.109706_bb0145","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1200\/JCO.2012.44.5353","article-title":"ALK in lung Cancer: past, present, and future","volume":"31","author":"Shaw","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2026.109706_bb0150","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1038\/nm.3930","article-title":"RAS\u2013MAPK dependence underlies a rational polytherapy strategy in EML4\u2013ALK-positive lung cancer","volume":"21","author":"Hrustanovic","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.bioorg.2026.109706_bb0155","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41392-019-0101-6","article-title":"PROTACs: great opportunities for academia and industry","volume":"4","author":"Sun","year":"2019","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bioorg.2026.109706_bb0160","first-page":"4567","article-title":"PROTACs for ALK degradation: overcoming resistance in ALK-positive cancers","volume":"66","author":"Zhang","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109706_bb0165","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1021\/acs.jmedchem.7b01272","article-title":"PROTAC-induced protein degradation in drug discovery: breaking the rules or just making new ones?","volume":"61","author":"Churcher","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109706_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.112025","article-title":"Dual-target kinase drug design: current strategies and future directions in Cancer therapy","volume":"188","author":"Sun","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109706_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106653","article-title":"Discovery of potent and effective inhibitors containing sulfoxide structures targeting EML4\u2013ALK rearrangement and EGFR mutant non-Small cell lung Cancer","volume":"138","author":"An","year":"2023","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.109706_bb0180","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1158\/2159-8290.CD-16-1123","article-title":"Targeting ALK: precision medicine takes on drug resistance","volume":"7","author":"Lin","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bioorg.2026.109706_bb0185","first-page":"5520","article-title":"Brigatinib (AP26113) overcomes mechanisms of resistance to first- and second-generation ALK inhibitors in non\u2013Small-cell lung Cancer","volume":"22","author":"Sakamoto","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.109706_bb0190","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1158\/2159-8290.CD-16-1237","article-title":"Safety and antitumor activity of the multitarget TRK, ROS1, and ALK inhibitor Entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1)","volume":"7","author":"Drilon","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bioorg.2026.109706_bb0195","article-title":"Cabozantinib for the treatment of advanced medullary thyroid Cancer and other malignancies","volume":"81","author":"Cabanillas","year":"2019","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.bioorg.2026.109706_bb0200","first-page":"1561","article-title":"Brigatinib in Crizotinib-resistant ALK+ NSCLC: Long-term efficacy and safety results","volume":"16","author":"Gainor","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.bioorg.2026.109706_bb0205","article-title":"Properties of FDA-approved Small molecule protein kinase inhibitors: a 2024 update","volume":"199","author":"Roskoski","year":"2024","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bioorg.2026.109706_bb0210","article-title":"Overview of the structural biology of ALK and clinical implications","volume":"1876","author":"Wu","year":"2021","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"10.1016\/j.bioorg.2026.109706_bb0215","first-page":"5729","article-title":"Mechanisms of resistance to ALK kinase inhibitors in ALK-positive lung cancer","volume":"22","author":"Gainor","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.109706_bb0220","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","article-title":"Tumour heterogeneity and resistance to Cancer therapies","volume":"15","author":"Dagogo-Jack","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2026.109706_bb0225","doi-asserted-by":"crossref","first-page":"4720","DOI":"10.1021\/jm500261q","article-title":"Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]benzoxadiazacyclo-tetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of ALK and ROS1","volume":"57","author":"Johnson","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109706_bb0230","article-title":"Structure-based design of next-generation ALK inhibitors: overcoming resistance mutations","volume":"204","author":"Liu","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109706_bb0235","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1158\/2159-8290.CD-13-0846","article-title":"The ALK inhibitor lorlatinib overcomes resistance to first- and second-generation ALK inhibitors in non\u2013small-cell lung cancer","volume":"4","author":"Friboulet","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bioorg.2026.109706_bb0240","first-page":"8367","article-title":"Medicinal chemistry strategies for enhancing CNS penetration of kinase inhibitors","volume":"64","author":"Li","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109706_bb0245","first-page":"3292","article-title":"PF-06463922, a potent and selective ALK\/ROS1 inhibitor, demonstrates robust preclinical efficacy against resistant mutations and CNS metastases","volume":"21","author":"Zou","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.109706_bb0250","first-page":"632","article-title":"Repotrectinib efficacy in ROS1+ and ALK+ non\u2013small-cell lung cancer: preclinical and clinical data","volume":"33","author":"Ou","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bioorg.2026.109706_bb0255","first-page":"10001","article-title":"Structural insights into resistance and the evolution of ALK-targeted therapies","volume":"65","author":"Galkin","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109706_bb0260","first-page":"1085","article-title":"Advances in macrocyclic kinase inhibitors: design principles and therapeutic potential","volume":"43","author":"Lutterbach","year":"2023","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.bioorg.2026.109706_bb0265","article-title":"Dual and multitarget ALK inhibitors: medicinal chemistry advances and therapeutic perspectives","volume":"259","author":"Zeng","year":"2024","journal-title":"Eur. J. Med. Chem."},{"issue":"18","key":"10.1016\/j.bioorg.2026.109706_bb0270","doi-asserted-by":"crossref","first-page":"6342","DOI":"10.1021\/jm2007613","article-title":"Structure-based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal\u2013epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK)","volume":"54","author":"Cui","year":"2011","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.bioorg.2026.109706_bb0275","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djt378","article-title":"Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients","volume":"106","author":"Gambacorti-Passerini","year":"2014","journal-title":"J. Natl. Cancer Inst."},{"issue":"10","key":"10.1016\/j.bioorg.2026.109706_bb0280","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1158\/1078-0432.CCR-14-2791","article-title":"Therapeutic targeting of anaplastic lymphoma kinase in lung Cancer: a paradigm for precision Cancer medicine","volume":"21","author":"Katayama","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"Suppl. 1","key":"10.1016\/j.bioorg.2026.109706_bb0285","article-title":"Crizotinib in advanced ALK+ anaplastic large cell lymphoma in children and adults: results of the ACS phase II trial","volume":"130","author":"Brugi\u00e8res","year":"2017","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.bioorg.2026.109706_bb0290","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1158\/1535-7163.MCT-07-0365","article-title":"Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-met, in experimental models of anaplastic large-cell lymphoma","volume":"6","author":"Christensen","year":"2007","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bioorg.2026.109706_bb0295","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.phrs.2017.01.007","article-title":"Anaplastic lymphoma kinase (ALK) inhibitors in the treatment of ALK-driven lung cancers","volume":"117","author":"Roskoski","year":"2017","journal-title":"Pharmacol. Res."},{"issue":"6","key":"10.1016\/j.bioorg.2026.109706_bb0300","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1158\/2159-8290.CD-13-0846","article-title":"The ALK inhibitor ceritinib overcomes crizotinib resistance in non\u2013small cell lung cancer","volume":"4","author":"Friboulet","year":"2014","journal-title":"Cancer Discov."},{"issue":"16","key":"10.1016\/j.bioorg.2026.109706_bb0305","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1080\/14656566.2016.1242578","article-title":"Current and developing therapies for the treatment of non-Small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice","volume":"17","author":"Caccese","year":"2016","journal-title":"Expert. Opin. Pharmacother."},{"issue":"14","key":"10.1016\/j.bioorg.2026.109706_bb0310","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.1021\/jm400402q","article-title":"Synthesis, structure\u2013activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor LDK378 currently in phase 1 and phase 2 clinical trials","volume":"56","author":"Marsilje","year":"2013","journal-title":"J. Med. Chem."},{"issue":"11","key":"10.1016\/j.bioorg.2026.109706_bb0315","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1158\/1078-0432.CCR-14-3157","article-title":"FDA approval: ceritinib for the treatment of metastatic anaplastic lymphoma kinase\u2013positive non\u2013small cell lung cancer","volume":"21","author":"Khozin","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.bioorg.2026.109706_bb0320","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1002\/cam4.413","article-title":"Activity of second-generation ALK inhibitors against Crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK","volume":"4","author":"Fontana","year":"2015","journal-title":"Cancer Med."},{"key":"10.1016\/j.bioorg.2026.109706_bb0325","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1177\/1758834015617355","article-title":"ALK inhibitors in non-Small cell lung Cancer: the latest evidence and developments","volume":"8","author":"Sullivan","year":"2016","journal-title":"Ther. Adv. Med. Oncol"},{"key":"10.1016\/j.bioorg.2026.109706_bb0330","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1021\/jm400378w","article-title":"KLIFS: a knowledge-based structural database to navigate kinase\u2013ligand interaction space","volume":"57","author":"van Linden","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109706_bb0335","doi-asserted-by":"crossref","first-page":"5171","DOI":"10.1158\/1078-0432.CCR-16-1293","article-title":"FDA approval: Alectinib for the treatment of metastatic, ALK-positive non-Small cell lung Cancer following Crizotinib","volume":"22","author":"Larkins","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.109706_bb0340","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.apsb.2014.12.007","article-title":"Alectinib: a novel second-generation anaplastic lymphoma kinase (ALK) inhibitor for overcoming clinically acquired resistance","volume":"5","author":"Song","year":"2015","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.bioorg.2026.109706_bb0345","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1007\/s40265-017-0776-3","article-title":"Brigatinib: first global approval","volume":"77","author":"Markham","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.bioorg.2026.109706_bb0350","doi-asserted-by":"crossref","first-page":"4948","DOI":"10.1021\/acs.jmedchem.6b00306","article-title":"Discovery of Brigatinib (AP26113), a phosphine oxide-containing, potent, orally active inhibitor of anaplastic lymphoma kinase","volume":"59","author":"Huang","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109706_bb0355","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.semcdb.2016.09.016","article-title":"Drug resistance in ALK-positive non-Small cell lung Cancer patients","volume":"64","author":"Qian","year":"2017","journal-title":"Semin. Cell Dev. Biol."},{"key":"10.1016\/j.bioorg.2026.109706_bb0360","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/7355_2017_18","article-title":"Small-molecule inhibitors of ALK","volume":"28","author":"Hatcher","year":"2017","journal-title":"Topics Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109706_bb0365","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1158\/1535-7163.MCT-15-0758","article-title":"Entrectinib, a Pan-TRK, ROS1, and ALK inhibitor with activity in multiple molecularly defined Cancer indications","volume":"15","author":"Ardini","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bioorg.2026.109706_bb0370","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1021\/acs.jmedchem.6b00064","article-title":"Discovery of Entrectinib: a new 3-Aminoindazole as a potent anaplastic lymphoma kinase (ALK), c-ROS oncogene 1 kinase (ROS1), and Pan-tropomyosin receptor kinase (Pan-TRK) inhibitor","volume":"59","author":"Menichincheri","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109706_bb0375","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1007\/s40265-019-01177-y","article-title":"Entrectinib: first global approval","volume":"79","author":"Al-Salama","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.bioorg.2026.109706_bb0380","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1080\/14756366.2019.1639694","article-title":"Identification of 1H-Pyrazolo[3,4-b]pyridine derivatives as potent ALK-L1196M inhibitors","volume":"34","author":"Nam","year":"2019","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109706_bb0385","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1007\/s40265-023-01970-w","article-title":"Iruplinalkib: first approval","volume":"83","author":"Keam","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.bioorg.2026.109706_bb0390","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.128730","article-title":"Discovery and preclinical evaluations of WX-0593, a novel ALK inhibitor targeting Crizotinib-resistant mutations","volume":"66","author":"Liu","year":"2022","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2026.109706_bb0395","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s10637-023-01350-x","article-title":"Iruplinalkib (WX-0593), a novel ALK\/ROS1 inhibitor, overcomes Crizotinib resistance in preclinical models for non-Small cell lung cancer","volume":"41","author":"Yang","year":"2023","journal-title":"Investig. New Drugs"},{"key":"10.1016\/j.bioorg.2026.109706_bb0400","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s40265-018-1041-0","article-title":"Y. Lorlatinib: first global approval","volume":"79","author":"Syed","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.bioorg.2026.109706_bb0405","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ccell.2015.05.010","article-title":"PF-06463922, an ALK\/ROS1 inhibitor, overcomes resistance to first- and second-generation ALK inhibitors in preclinical models","volume":"28","author":"Zou","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bioorg.2026.109706_bb0410","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1016\/S0959-8049(16)32675-2","article-title":"TPX-0005, a novel ALK\/ROS1\/TRK inhibitor, effectively inhibited a broad Spectrum of mutations including solvent-front ALK G1202R, ROS1 G2032R and TRKA G595R mutants","volume":"69","author":"Cui","year":"2016","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.bioorg.2026.109706_bb0415","doi-asserted-by":"crossref","first-page":"S1164","DOI":"10.1016\/j.jtho.2016.11.1639","article-title":"P3.02a-009 TPX-0005: a multi-faceted approach to overcoming clinical resistances from current ALK or ROS1 inhibitor treatment in lung Cancer","volume":"12","author":"Cui","year":"2017","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.bioorg.2026.109706_bb0420","doi-asserted-by":"crossref","first-page":"B186","DOI":"10.1158\/1535-7163.TARG-17-B186","article-title":"Abstract B186: TPX-0005, a Polypharmacology inhibitor, overcomes ALK treatment resistance from acquired mutations, bypass signaling, and EMT","volume":"17","author":"Zhai","year":"2018","journal-title":"Mol. Cancer Ther."},{"issue":"13","key":"10.1016\/j.bioorg.2026.109706_bb0425","doi-asserted-by":"crossref","first-page":"4795","DOI":"10.1158\/1538-7445.AM2018-4795","article-title":"Abstract 4795: potency of a new ALK\/ROS1 inhibitor TPX-0005 to ALK G1202R mutation and ROS1 G2032R mutation","volume":"78","author":"Yoda","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2026.109706_bb0430","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1056\/NEJMoa2302299","article-title":"Repotrectinib in ROS1 fusion\u2013positive non\u2013small-cell lung cancer","volume":"390","author":"Drilon","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bioorg.2026.109706_bb0435","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2018.10.019","article-title":"Preliminary clinical activity of repotrectinib (TPX-0005) in advanced ROS1 fusion\u2013positive non\u2013small-cell lung cancer","volume":"13","author":"Ou","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.bioorg.2026.109706_bb0440","series-title":"The Novel, rationally designed ALK\/SRC inhibitor TPX-0005 overcomes multiple acquired resistance mechanisms to current ALK inhibitors","author":"Zhai","year":"2016"},{"issue":"16 Suppl","key":"10.1016\/j.bioorg.2026.109706_bb0445","article-title":"TPX-0131: a next-generation macrocyclic ALK inhibitor that overcomes ALK-resistant mutations refractory to currently approved ALK inhibitors","volume":"80","author":"Cui","year":"2020","journal-title":"Cancer Res."},{"issue":"9","key":"10.1016\/j.bioorg.2026.109706_bb0450","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1158\/1535-7163.MCT-21-0221","article-title":"TPX-0131, a potent CNS-penetrant, next-generation inhibitor of wild-type ALK and ALK-resistant mutations","volume":"20","author":"Murray","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bioorg.2026.109706_bb0455","series-title":"Study of NVL-655 in patients with advanced NSCLC and other solid tumors harboring ALK rearrangement or activating ALK mutation (ALKOVE-1)","author":"Nuvalent Inc","year":"2022"},{"key":"10.1016\/j.bioorg.2026.109706_bb0460","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.lungcan.2014.12.017","article-title":"Future options for ALK-positive non-small cell lung cancer","volume":"87","author":"Iacono","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.bioorg.2026.109706_bb0465","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s12032-022-01770-4","article-title":"Differential molecular mechanistic behavior of HDACs in Cancer progression","volume":"39","author":"Singh","year":"2022","journal-title":"Med. Oncol."},{"key":"10.1016\/j.bioorg.2026.109706_bb0470","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2020.582370","article-title":"Histone deacetylase inhibition in non-Small cell lung Cancer: hype or Hope?","volume":"8","author":"Mamdani","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.bioorg.2026.109706_bb0475","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.bonr.2017.08.001","article-title":"Histone deacetylases and their roles in mineralized tissue regeneration","volume":"7","author":"Huynh","year":"2017","journal-title":"Bone Rep."},{"key":"10.1016\/j.bioorg.2026.109706_bb0480","first-page":"579","article-title":"Histone deacetylases and Cancer. Mol","volume":"6","author":"Barneda-Zahonero","year":"2012","journal-title":"Oncol"},{"key":"10.1016\/j.bioorg.2026.109706_bb0485","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s00280-013-2223-9","article-title":"Histones and lung Cancer: are the histone deacetylases a promising therapeutic target?","volume":"72","author":"Petta","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.bioorg.2026.109706_bb0490","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a026831","article-title":"HDACs and HDAC inhibitors in Cancer development and therapy","volume":"6","author":"Li","year":"2016","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.bioorg.2026.109706_bb0495","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2022.960263","article-title":"Histone deacetylases modulate resistance to therapy in lung Cancer","volume":"13","author":"Contreras-Sanz\u00f3n","year":"2022","journal-title":"Front. Genet."},{"key":"10.1016\/j.bioorg.2026.109706_bb0500","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2021.101312","article-title":"HDAC inhibitors: targets for tumor therapy, immune modulation and lung diseases","volume":"16","author":"Shanmugam","year":"2022","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.bioorg.2026.109706_bb0505","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1016\/j.apsb.2023.02.007","article-title":"Targeting histone deacetylases for Cancer therapy: trends and challenges","volume":"13","author":"Liang","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.bioorg.2026.109706_bb0510","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2020.578011","article-title":"Synergistic enhancement of Cancer therapy using HDAC inhibitors: opportunity for clinical trials","volume":"11","author":"Hontecillas-Prieto","year":"2020","journal-title":"Front. Genet."},{"key":"10.1016\/j.bioorg.2026.109706_bb0515","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.lungcan.2020.04.002","article-title":"HDAC inhibition synergizes with ALK inhibitors to overcome resistance in a novel ALK-mutated lung adenocarcinoma model","volume":"144","author":"Stockhammer","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.bioorg.2026.109706_bb0520","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113672","article-title":"Discovery of 2,4-Pyrimidinediamine derivatives as potent dual inhibitors of ALK and HDAC","volume":"224","author":"Pan","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109706_bb0525","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1080\/14756366.2022.2121822","article-title":"Design, synthesis, and biological evaluation of 2,4-Pyrimidinediamine derivatives as ALK and HDAC dual inhibitors for the treatment of ALK-addicted Cancer","volume":"37","author":"Guo","year":"2022","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109706_bb0530","doi-asserted-by":"crossref","DOI":"10.1080\/14756366.2024.2318645","article-title":"Discovery of novel anaplastic lymphoma kinase (ALK) and histone deacetylase (HDAC) dual inhibitors exhibiting Antiproliferative activity against non-Small cell lung Cancer","volume":"39","author":"Wang","year":"2024","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109706_bb0535","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.apsb.2020.05.004","article-title":"Development of Small-molecule tropomyosin receptor kinase (TRK) inhibitors for NTRK fusion cancers","volume":"11","author":"Jiang","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.bioorg.2026.109706_bb0540","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid Tumours: integrated analysis of three phase 1\u20132 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bioorg.2026.109706_bb0545","doi-asserted-by":"crossref","first-page":"4974","DOI":"10.1158\/1078-0432.CCR-21-0465","article-title":"Tropomyosin receptor kinase inhibitors for the treatment of TRK fusion Cancer","volume":"27","author":"Laetsch","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.109706_bb0550","doi-asserted-by":"crossref","first-page":"5807","DOI":"10.1158\/1078-0432.CCR-18-1156","article-title":"Emerging targeted therapy for tumors with NTRK fusion proteins","volume":"24","author":"Kheder","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.109706_bb0555","doi-asserted-by":"crossref","first-page":"1","DOI":"10.21037\/pcm-23-19","article-title":"NTRK1\/2\/3: biology, detection and therapy","volume":"6","author":"Bungaro","year":"2024","journal-title":"Precision Cancer Medicine"},{"key":"10.1016\/j.bioorg.2026.109706_bb0560","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/LCTT.S16313","article-title":"Targeted inhibition in tumors with ALK dependency","volume":"4","author":"Kwak","year":"2013","journal-title":"Lung Cancer Targets Ther."},{"key":"10.1016\/j.bioorg.2026.109706_bb0565","first-page":"1744","article-title":"Resistance to TRK inhibition mediated by multiple on-target kinase domain mutations","volume":"27","author":"Cocco","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.109706_bb0570","doi-asserted-by":"crossref","first-page":"4915","DOI":"10.1021\/acs.jmedchem.8b01630","article-title":"Discovery of potent, selective, and brain-penetrant 1H-Pyrazol-5-yl-1H-pyrrolo[2,3-b]pyridines as anaplastic lymphoma kinase (ALK) inhibitors","volume":"62","author":"Fushimi","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109706_bb0575","doi-asserted-by":"crossref","first-page":"31984","DOI":"10.1021\/acsomega.0c04900","article-title":"Discovery of novel and highly selective cyclopropane ALK inhibitors through a fragment-assisted, structure-based drug design","volume":"5","author":"Fujimori","year":"2020","journal-title":"ACS Omega"},{"key":"10.1016\/j.bioorg.2026.109706_bb0580","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2021.116396","article-title":"Discovery of novel 2-Phenylamino-4-Prolylpyrimidine derivatives as TRK\/ALK dual inhibitors with promising antitumor effects","volume":"47","author":"Li","year":"2021","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109706_bb0585","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106563","article-title":"Discovery of novel phenyl Triazole analogs as TRK\/ALK dual inhibitors with prospective antitumor effects","volume":"136","author":"Cao","year":"2023","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.109706_bb0590","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.128646","article-title":"Pyrizolo[1,5-a]pyrimidine derivatives of the second-generation TRK inhibitor: design, synthesis, and biological evaluation","volume":"63","author":"Fan","year":"2022","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2026.109706_bb0595","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115918","article-title":"Design and synthesis of certain 7-Aryl-2-Methyl-3-substituted Pyrazolo[1,5-a]pyrimidines as multikinase inhibitors","volume":"262","author":"Al-Qadhi","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109706_bb0600","series-title":"Macrocyclic compounds as kinase inhibitors and uses thereof","author":"Wu","year":"2021"},{"key":"10.1016\/j.bioorg.2026.109706_bb0605","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/nrc2088","article-title":"Epidermal growth factor receptor mutations in lung cancer","volume":"7","author":"Sharma","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bioorg.2026.109706_bb0610","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.lungcan.2020.09.012","article-title":"Distribution of EML4\u2013ALK fusion variants and clinical outcomes in patients with resected non\u2013small cell lung cancer","volume":"149","author":"Tao","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.bioorg.2026.109706_bb0615","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.2147\/DDDT.S196189","article-title":"Frequency, clinical features, and differential response to therapy of concurrent ALK\/EGFR alterations in chinese lung cancer patients","volume":"13","author":"Liu","year":"2019","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.bioorg.2026.109706_bb0620","first-page":"137","article-title":"A Long-term survivor of non\u2013small-cell lung cancer harboring concomitant EGFR mutation and ALK translocation","volume":"19","author":"Imamura","year":"2016","journal-title":"Respir. Med. Case. Rep."},{"key":"10.1016\/j.bioorg.2026.109706_bb0625","doi-asserted-by":"crossref","first-page":"6051","DOI":"10.1158\/0008-5472.CAN-11-1340","article-title":"A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors","volume":"71","author":"Sasaki","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2026.109706_bb0630","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1158\/1535-7163.MCT-15-0084","article-title":"Activation of EGFR bypass signaling by TGF\u03b1 overexpression induces acquired resistance to Alectinib in ALK-translocated lung Cancer cells","volume":"15","author":"Tani","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bioorg.2026.109706_bb0635","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1158\/1541-7786.MCR-16-0211","article-title":"Overcoming EGFR bypass signal\u2013induced acquired resistance to ALK tyrosine kinase inhibitors in ALK-translocated lung cancer","volume":"15","author":"Miyawaki","year":"2017","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.109706_bb0640","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2023.117241","article-title":"Synthesis and evaluation of sulfonamide derivatives targeting EGFR T790M\/L858R mutations and ALK rearrangement as anticancer agents","volume":"85","author":"Cao","year":"2023","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109706_bb0645","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.106188","article-title":"Discovery of a potent EGFR and ALK dual mutation inhibitor containing an N-(3-((4-((2-(Cyclopropylsulfinyl)phenyl)amino)pyrimidin-2-yl)amino)phenyl)acrylamide scaffold","volume":"129","author":"Li","year":"2022","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.109706_bb0650","article-title":"Synthesis of novel deuterated EGFR\/ALK dual-target inhibitors and their activity against non\u2013small cell lung cancer","volume":"283","author":"Nie","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109706_bb0655","first-page":"28","article-title":"Novel dual-target kinase inhibitors of EGFR and ALK were designed, synthesized, and induced cell apoptosis in non-small cell lung cancer","volume":"2023","author":"Fan","year":"2006","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2026.109706_bb0660","doi-asserted-by":"crossref","first-page":"4846","DOI":"10.1038\/ncomms5846","article-title":"The landscape of kinase fusions in Cancer","volume":"5","author":"Stransky","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bioorg.2026.109706_bb0665","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/nm.2658","article-title":"RET, ROS1, and ALK fusions in lung Cancer","volume":"18","author":"Takeuchi","year":"2012","journal-title":"Nat. Med."},{"key":"10.1016\/j.bioorg.2026.109706_bb0670","article-title":"Survey of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma","volume":"6","author":"Gu","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.bioorg.2026.109706_bb0675","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0028250","article-title":"Chromosome 3 anomalies investigated by genome-wide SNP analysis of benign, low malignant potential, and low-grade ovarian serous Tumours","volume":"6","author":"Birch","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.bioorg.2026.109706_bb0680","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1003464","article-title":"Breakpoint analysis of transcriptional and genomic profiles uncovers novel gene fusions spanning multiple human cancer types","volume":"9","author":"Giacomini","year":"2013","journal-title":"PLoS Genet."},{"key":"10.1016\/j.bioorg.2026.109706_bb0685","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.1038\/ncomms4116","article-title":"Kinase fusions are frequent in Spitz Tumours and Spitzoid melanomas","volume":"5","author":"Wiesner","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bioorg.2026.109706_bb0690","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1586\/era.12.17","article-title":"ROS1 as a \u201cDruggable\u201d receptor tyrosine kinase: lessons learned from inhibiting the ALK pathway","volume":"12","author":"Ou","year":"2012","journal-title":"Expert. Rev. Anticancer. Ther."},{"key":"10.1016\/j.bioorg.2026.109706_bb0695","doi-asserted-by":"crossref","DOI":"10.1080\/14756366.2023.2227779","article-title":"Discovery of novel 2-Aminopyridine derivatives as ROS1 and ALK dual inhibitors to combat drug-resistant mutants including ROS1 G2032R and ALK G1202R","volume":"38","author":"Liu","year":"2023","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109706_bb0700","article-title":"Discovery of 2-Aminopyridines bearing a Pyridone moiety as potent ALK inhibitors to overcome the Crizotinib-resistant mutants","volume":"138","author":"Chen","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109706_bb0705","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2020.115719","article-title":"Fragment-based modification of 2,4-Diarylaminopyrimidine derivatives as ALK and ROS1 dual inhibitors to overcome secondary mutants","volume":"28","author":"Zhu","year":"2020","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109706_bb0710","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113259","article-title":"Structure-based optimization identified novel Furyl-containing 2,4-Diarylaminopyrimidine analogues as ALK\/ROS1 dual inhibitors with anti-mutation effects","volume":"214","author":"Guo","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109706_bb0715","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2019.114781","article-title":"A novel ALK inhibitor ZYY inhibits Karpas299 cell growth in vitro and in a nude mouse xenograft model and induces protective autophagy","volume":"383","author":"Shen","year":"2019","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.bioorg.2026.109706_bb0720","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.ejmech.2019.03.038","article-title":"Discovery of novel mutant-combating ALK and ROS1 dual inhibitors bearing Imidazolidin-2-one moiety with reasonable PK properties","volume":"171","author":"Lei","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109706_bb0725","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2019.115051","article-title":"An exploration of solvent-front region high-affinity moiety leading to novel potent ALK and ROS1 dual inhibitors with mutant-combating effects","volume":"27","author":"Lei","year":"2019","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109706_bb0730","article-title":"Structure-based design of 2,4-diaminopyrimidine derivatives bearing a pyrrolyl group as ALK and ROS1 inhibitors","author":"Wang","year":"2020","journal-title":"New J. Chem."},{"key":"10.1016\/j.bioorg.2026.109706_bb0735","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.ejmech.2019.06.043","article-title":"Design, synthesis, and biological evaluations of 2-Amino-4-(1-Piperidine)pyridine derivatives as novel anti\u2013Crizotinib-resistant ALK\/ROS1 dual inhibitors","volume":"179","author":"Liu","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109706_bb0740","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.ejmech.2018.09.012","article-title":"Dual potent ALK and ROS1 inhibitors combating drug-resistant mutants: synthesis and biological evaluation of Aminopyridine-containing Diarylaminopyrimidine derivatives","volume":"158","author":"Guo","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109706_bb0745","series-title":"Compound used as kinase inhibitor and application thereof","author":"Li","year":"2022"},{"key":"10.1016\/j.bioorg.2026.109706_bb0750","series-title":"Chiral Diaryl macrocycles as modulators of protein kinases","author":"Cui","year":"2021"},{"key":"10.1016\/j.bioorg.2026.109706_bb0755","series-title":"Macrolide Derivatives, Preparation Method, and Application Thereof","author":"Chen","year":"2022"},{"key":"10.1016\/j.bioorg.2026.109706_bb0760","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ejmech.2017.11.002","article-title":"Design, synthesis, biological evaluation, and molecular modeling of novel 2-Amino-4-(1-Phenylethoxy)pyridine derivatives as potential ROS1 inhibitors","volume":"143","author":"Tian","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109706_bb0765","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ejmech.2017.11.008","article-title":"Discovery of novel 2,4-Diarylaminopyrimidine analogues as ALK and ROS1 dual inhibitors to overcome Crizotinib-resistant mutants including G1202R","volume":"143","author":"Wang","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109706_bb0770","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1186\/s12885-022-09799-4","article-title":"Discovery of a novel ALK\/ROS1\/FAK inhibitor, APG-2449, in preclinical non-small cell lung cancer and ovarian cancer models","volume":"22","author":"Fang","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bioorg.2026.109706_bb0775","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.108014","article-title":"Revealing 5-(3,5-Difluorobenzyl)-1H-Indazole as the active pharmacophore of ALK\/ROS1 dual inhibitors through theoretical calculations and biological activity evaluations","volume":"154","author":"Huang","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.109706_bb0780","doi-asserted-by":"crossref","first-page":"13141","DOI":"10.1074\/jbc.R700001200","article-title":"The double Bromodomain-containing chromatin adaptor Brd4 and transcriptional regulation","volume":"282","author":"Wu","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bioorg.2026.109706_bb0785","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.4161\/cc.8.20.9522","article-title":"MYC, microRNAs, and glutamine addiction in cancers","volume":"8","author":"Dang","year":"2009","journal-title":"Cell Cycle"},{"key":"10.1016\/j.bioorg.2026.109706_bb0790","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/nature08822","article-title":"The landscape of somatic copy-number alteration across human cancers","volume":"463","author":"Beroukhim","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2026.109706_bb0795","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.hoc.2009.11.011","article-title":"Neuroblastoma: biology, prognosis, and treatment","volume":"24","author":"Park","year":"2010","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"10.1016\/j.bioorg.2026.109706_bb0800","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ccr.2012.06.001","article-title":"The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma","volume":"22","author":"Berry","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bioorg.2026.109706_bb0805","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1158\/2159-8290.CD-12-0418","article-title":"Targeting MYCN in neuroblastoma by BET Bromodomain inhibition","volume":"3","author":"Puissant","year":"2013","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bioorg.2026.109706_bb0810","doi-asserted-by":"crossref","first-page":"5814","DOI":"10.1158\/1078-0432.CCR-13-0680","article-title":"New strategies in neuroblastoma: therapeutic targeting of MYCN and ALK","volume":"19","author":"Barone","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.109706_bb0815","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nrd4286","article-title":"Targeting Bromodomains: epigenetic readers of lysine acetylation","volume":"13","author":"Filippakopoulos","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bioorg.2026.109706_bb0820","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1021\/acs.jmedchem.8b01947","article-title":"Designing dual inhibitors of anaplastic lymphoma kinase (ALK) and Bromodomain-4 (BRD4) by tuning kinase selectivity","volume":"62","author":"Watts","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109706_bb0825","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0065-230X(08)00002-X","article-title":"TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human Cancer","volume":"100","author":"Linger","year":"2008","journal-title":"Adv. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.109706_bb0830","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/nrc3847","article-title":"The TAM family: phosphatidylserine-sensing receptor tyrosine kinases gone awry in Cancer","volume":"14","author":"Graham","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bioorg.2026.109706_bb0835","doi-asserted-by":"crossref","first-page":"3231","DOI":"10.1172\/JCI67655","article-title":"MerTK inhibition in tumor leukocytes decreases tumor growth and metastasis","volume":"123","author":"Cook","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bioorg.2026.109706_bb0840","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1200\/JCO.2012.45.2029","article-title":"Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung Cancer","volume":"31","author":"Gainor","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2026.109706_bb0845","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1182\/blood-2014-06-583062","article-title":"Mer tyrosine kinase promotes the survival of t(1;19)-positive acute lymphoblastic leukemia in the central nervous system","volume":"125","author":"Wang","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.bioorg.2026.109706_bb0850","doi-asserted-by":"crossref","first-page":"13994","DOI":"10.1021\/acs.jmedchem.0c01550","article-title":"Discovery of CJ-2360 as a potent and orally active inhibitor of anaplastic lymphoma kinase capable of achieving complete tumor regression","volume":"63","author":"Chen","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109706_bb0855","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1158\/1078-0432.CCR-16-1114","article-title":"Dual ALK and CDK4\/6 inhibition demonstrates on-target synergy against neuroblastoma","volume":"23","author":"Wood","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.109706_bb0860","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s13045-020-00880-8","article-title":"The application and Prospect of CDK4\/6 inhibitors in malignant solid tumors","volume":"13","author":"Zhou","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bioorg.2026.109706_bb0865","article-title":"CDK4\/6 inhibitors in combination therapies: better in company than alone\u2014a Mini review","volume":"12","author":"Franci","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bioorg.2026.109706_bb0870","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.115082","article-title":"Discovery of the GSH-responsive \u201cY-PROTACs\u201d targeting ALK and CDK4\/6 as a potential treatment for Cancer","volume":"248","author":"Wang","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109706_bb0875","first-page":"1113","article-title":"Expression and signal transduction of the FLT3 receptor in human hematopoietic progenitor cells","volume":"87","author":"Rosnet","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.bioorg.2026.109706_bb0880","first-page":"1169","article-title":"FLT3 mutations: biology and treatment","volume":"107","author":"Small","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bioorg.2026.109706_bb0885","first-page":"3616","article-title":"The role of FLT3 in hematopoietic malignancies","volume":"102","author":"Stirewalt","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bioorg.2026.109706_bb0890","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","article-title":"Targeting FLT3 mutations in AML: review of current knowledge and future directions","volume":"33","author":"Daver","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.bioorg.2026.109706_bb0895","first-page":"1461","article-title":"Cross-activation of FLT3 and ALK pathways contributes to therapeutic resistance in leukemia and lung cancer models","volume":"20","author":"Phung","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bioorg.2026.109706_bb0900","article-title":"Design, synthesis, and biological evaluation of dual ALK\/FLT3 inhibitors based on a 2,4-diaminopyrimidine scaffold","volume":"250","author":"Wang","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109706_bb0905","article-title":"Discovery of indolocarbazole-based kinase inhibitors targeting both ALK and FLT3 pathways","volume":"128","author":"Zhang","year":"2022","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.109706_bb0910","first-page":"3297","article-title":"Gilteritinib, a dual FLT3\/ALK inhibitor for relapsed or refractory acute myeloid leukemia: preclinical and clinical evaluation","volume":"23","author":"Mori","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.109706_bb0915","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/cas.14274","article-title":"FLT3 mutations in acute myeloid leukemia: therapeutic paradigm beyond inhibitor development","volume":"111","author":"Kiyoi","year":"2020","journal-title":"Cancer Sci."},{"key":"10.1016\/j.bioorg.2026.109706_bb0920","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107204","article-title":"Expansion of targeted degradation by Gilteritinib-Warheaded PROTACs to ALK fusion proteins","volume":"145","author":"Yokoo","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.109706_bb0925","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/nrd4281","article-title":"Targeting RAS\u2013ERK signaling in Cancer: promises and challenges","volume":"13","author":"Samatar","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bioorg.2026.109706_bb0930","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1126\/science.1141478","article-title":"MET amplification leads to Gefitinib resistance by activating ERBB3 signaling","volume":"316","author":"Engelman","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.bioorg.2026.109706_bb0935","doi-asserted-by":"crossref","first-page":"120ra17","DOI":"10.1126\/scitranslmed.3003316","article-title":"Mechanisms of acquired Crizotinib resistance in ALK-rearranged lung cancers","volume":"4","author":"Katayama","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bioorg.2026.109706_bb0940","first-page":"236","article-title":"Combined inhibition of ALK and MEK enhances apoptosis in ALK-positive NSCLC models","volume":"17","author":"Ferguson","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bioorg.2026.109706_bb0945","first-page":"141","article-title":"Synergistic suppression of EML4\u2013ALK NSCLC by co-targeting ALK and MEK pathways","volume":"25","author":"Lutterbach","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.109706_bb0950","article-title":"Design of dual ALK\/MEK inhibitors: a multitarget approach to overcome resistance","volume":"213","author":"Menichincheri","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109706_bb0955","article-title":"Targeting the MAPK pathway in ALK-positive lung cancer: rationale and clinical perspectives","volume":"99","author":"Recondo","year":"2021","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.bioorg.2026.109706_bb0960","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2021.131066","article-title":"Pharmacophore screening, molecular docking, ADMET prediction and MD simulations for identification of ALK and MEK potential dual inhibitors","volume":"1245","author":"Zhang","year":"2021","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.bioorg.2026.109706_bb0965","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/nrm3012","article-title":"MET Signalling: principles and functions in development, organ regeneration and cancer","volume":"11","author":"Trusolino","year":"2010","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.bioorg.2026.109706_bb0970","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1038\/nrm1261","article-title":"MET, metastasis, motility and more","volume":"4","author":"Birchmeier","year":"2003","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.bioorg.2026.109706_bb0975","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1517\/14728222.2012.680957","article-title":"Targeting the HGF\/MET signaling pathway in cancer therapy","volume":"16","author":"Cecchi","year":"2012","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.bioorg.2026.109706_bb0980","first-page":"1497","article-title":"Dysregulated HGF\/c-MET signaling in cancer: pathways and therapeutic targeting","volume":"14","author":"Organ","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bioorg.2026.109706_bb0985","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/nrc3205","article-title":"Regulation of invasive growth by the MET\/HGF receptor","volume":"12","author":"Gherardi","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bioorg.2026.109706_bb0990","first-page":"206","article-title":"C-MET overexpression correlates with metastasis and poor prognosis in lung adenocarcinoma","volume":"19","author":"Peters","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.109706_bb0995","first-page":"618","article-title":"HGF\/c-MET Axis in hepatocellular carcinoma progression and therapy","volume":"17","author":"Zhou","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bioorg.2026.109706_bb1000","first-page":"1078","article-title":"MET amplification as a resistance mechanism to ALK inhibitors in lung Cancer","volume":"16","author":"Isozaki","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.bioorg.2026.109706_bb1005","first-page":"702","article-title":"Mechanisms of resistance to ALK inhibitors in NSCLC: c-MET amplification and beyond","volume":"10","author":"Recondo","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bioorg.2026.109706_bb1010","first-page":"2721","article-title":"HGF\/c-MET-mediated resistance to ALK inhibitors in lung adenocarcinoma and strategies to overcome it","volume":"26","author":"Katayama","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.109706_bb1015","first-page":"1541","article-title":"Pharmacologic characterization of CT-711, a novel dual inhibitor of ALK and c-met","volume":"8","author":"Wang","year":"2018","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.109706_bb1020","doi-asserted-by":"crossref","DOI":"10.1080\/10799893.2020.1735418","article-title":"Dual potent c-met and ALK inhibitors: from common-feature pharmacophore modeling to structure-based virtual screening","author":"Pirhadi","year":"2020","journal-title":"J. Recept. Signal Transduct."},{"key":"10.1016\/j.bioorg.2026.109706_bb1025","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1002\/j.1460-2075.1991.tb07841.x","article-title":"The ltk gene encodes a novel receptor-type protein tyrosine kinase","volume":"10","author":"Krolewski","year":"1991","journal-title":"EMBO J."},{"key":"10.1016\/j.bioorg.2026.109706_bb1030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0031733","article-title":"ALK-activating homologous mutations in LTK induce cellular transformation","volume":"7","author":"Roll","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.bioorg.2026.109706_bb1035","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.1083\/jcb.201903068","article-title":"LTK is an ER-resident receptor tyrosine kinase that regulates secretion","volume":"218","author":"Centonze","year":"2019","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.bioorg.2026.109706_bb1040","article-title":"Multifaceted roles of ALK family receptors and augmentor ligands in health and disease: a comprehensive review","volume":"13","author":"Casagrande","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.bioorg.2026.109706_bb1045","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/s41586-021-04135-5","article-title":"The CLIP1-LTK fusion: a new oncogenic driver in non-small-cell lung cancer?","volume":"600","author":"Roskoski","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2026.109706_bb1050","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202114296","article-title":"A new ALK inhibitor overcomes resistance to first- and second-generation inhibitors in NSCLC","volume":"14","author":"Lu","year":"2022","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.bioorg.2026.109706_bb1055","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/s41388-019-1016-y","article-title":"Heat-shock proteins: chaperoning DNA repair","volume":"39","author":"Dubrez","year":"2020","journal-title":"Oncogene"},{"key":"10.1016\/j.bioorg.2026.109706_bb1060","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s12192-008-0068-7","article-title":"Guidelines for the nomenclature of the human heat shock proteins","volume":"14","author":"Kampinga","year":"2009","journal-title":"Cell Stress Chaperones"},{"key":"10.1016\/j.bioorg.2026.109706_bb1065","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106721","article-title":"Small-molecule dual inhibitors targeting heat shock protein 90 for Cancer targeted therapy","author":"Xie","year":"2023","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.109706_bb1070","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.3390\/biom5042589","article-title":"Hsp90: a new player in DNA repair?","volume":"5","author":"Pennisi","year":"2015","journal-title":"Biomolecules"},{"key":"10.1016\/j.bioorg.2026.109706_bb1075","article-title":"HSP90: a promising target for NSCLC treatments","author":"Zhu","year":"2024","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bioorg.2026.109706_bb1080","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1016\/j.jmb.2019.05.026","article-title":"Intermolecular interactions between Hsp90 and Hsp70","volume":"431","author":"Doyle","year":"2019","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.bioorg.2026.109706_bb1085","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1007\/s00018-015-2117-6","article-title":"Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugs","volume":"73","author":"Bayliss","year":"2016","journal-title":"Cell. Mol. Life Sci."},{"issue":"Suppl. 15","key":"10.1016\/j.bioorg.2026.109706_bb1090","first-page":"e13007","article-title":"Preclinical Activity of the Hsp90 Inhibitor Ganetespib in ALK-Driven Tumor Models","volume":"30","author":"Proia","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2026.109706_bb1095","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ejmech.2018.04.019","article-title":"Design, synthesis, and pharmacological evaluation of ALK and Hsp90 dual inhibitors bearing resorcinol and 2,4-Diaminopyrimidine motifs","volume":"152","author":"Geng","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109706_bb1100","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.pharmthera.2014.10.001","article-title":"FAK signaling in human cancer as a target for therapeutics","volume":"146","author":"Lee","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bioorg.2026.109706_bb1105","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2020104743","article-title":"Structural basis of focal adhesion kinase activation on lipid membranes","volume":"39","author":"Acebron","year":"2020","journal-title":"EMBO J."},{"key":"10.1016\/j.bioorg.2026.109706_bb1110","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1517\/14728220903460340","article-title":"Targeting focal adhesion kinase signaling in tumor growth and metastasis","volume":"14","author":"Schwock","year":"2010","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.bioorg.2026.109706_bb1115","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.111073","article-title":"Pharmacological inhibition of focal adhesion kinase 1 (FAK1) and anaplastic lymphoma kinase (ALK) attenuates lipopolysaccharide-induced endothelial inflammatory activation","volume":"133","author":"Dayang","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bioorg.2026.109706_bb1120","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.cell.2015.09.001","article-title":"Nuclear FAK controls chemokine transcription, Tregs, and evasion of anti-tumor immunity","volume":"163","author":"Serrels","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.bioorg.2026.109706_bb1125","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41568-021-00340-6","article-title":"Targeting FAK in anticancer combination therapies","volume":"21","author":"Dawson","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bioorg.2026.109706_bb1130","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.111073","article-title":"Pharmacological inhibition of focal adhesion kinase 1 (FAK1) and anaplastic lymphoma kinase (ALK) attenuates lipopolysaccharide-induced endothelial inflammatory activation","volume":"133","author":"Dayang","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bioorg.2026.109706_bb1135","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1158\/1535-7163.MCT-11-0776","article-title":"CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers","volume":"11","author":"Cheng","year":"2012","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bioorg.2026.109706_bb1140","doi-asserted-by":"crossref","first-page":"7478","DOI":"10.1021\/acs.jmedchem.6b00487","article-title":"Discovery of clinical candidate CEP-37440, a selective inhibitor of focal adhesion kinase (FAK) and anaplastic lymphoma kinase (ALK)","volume":"59","author":"Ott","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109706_bb1145","series-title":"Methods for Treating Neuroblastoma With A Dual Anaplastic Lymphoma Kinase And Focal Adhesion Kinase Inhibitor","author":"Chinnaiyan","year":"2024"},{"key":"10.1016\/j.bioorg.2026.109706_bb1150","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1158\/1535-7163.MCT-06-0476","article-title":"Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo","volume":"6","author":"Liu","year":"2007","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bioorg.2026.109706_bb1155","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0003800","article-title":"Crystal structures of the FAK kinase in complex with TAE226 and related bis-anilino pyrimidine inhibitors reveal a helical DFG conformation","volume":"3","author":"Lietha","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.bioorg.2026.109706_bb1160","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/nrc3792","article-title":"FAK in cancer: mechanistic findings and clinical applications","volume":"14","author":"Sulzmaier","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bioorg.2026.109706_bb1165","first-page":"1788","article-title":"Phase I study of CEP-37440, a dual ALK and FAK inhibitor, in patients with advanced solid tumors","volume":"23","author":"Infante","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.109706_bb1170","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117328","article-title":"Discovery of 2,4-diaminopyrimidine derivatives as potent inhibitors of focal adhesion kinase capable of activating the hippo pathway for the treatment of esophageal squamous cell carcinoma","volume":"287","author":"Wang","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109706_bb1175","first-page":"11235","article-title":"Discovery and preclinical characterization of CT-707 (conteltinib), a potent FAK\/ALK\/Pyk2 multi-kinase inhibitor","volume":"63","author":"Zhao","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109706_bb1180","first-page":"4123","article-title":"Phase I study of CT-707 in patients with ALK-positive non-small cell lung cancer, including crizotinib-resistant disease","volume":"28","author":"Zhang","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.109706_bb1185","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1186\/s12916-022-02646-0","article-title":"Conteltinib (CT-707) in patients with advanced ALK-positive non-small cell lung cancer: a multicenter, open-label, first-in-human phase I study","volume":"20","author":"Xing","year":"2022","journal-title":"BMC Med."},{"key":"10.1016\/j.bioorg.2026.109706_bb1190","series-title":"Acceptance of CT-707 Granules for the Treatment of ALK-Positive Non-Small Cell Lung Cancer","author":"National Medical Products Administration (NMPA), China","year":"2024"}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826002427?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826002427?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T08:46:30Z","timestamp":1774860390000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206826002427"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":238,"alternative-id":["S0045206826002427"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.109706","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rational design of dual ALK inhibitors: scaffolds and strategies to circumvent drug resistance","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.109706","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109706"}}